JUVENIA is a unique and innovative veterinary product based on Resveratrol and introduced through a new dosage vehicle: NUTRAGEL.
NUTRAGEL is a high palatability gel which makes the dog eat voraciously when added to food, favoring the intake and facilitating continuity and adherence to treatment. In this manner, difficulties and traumas of the compulsory dosage of pills are dismissed.
JUVENIA DOGS was exclusively designed to be used whenever exists a necessity to increase or enhance the functions of defense, cognition, and metabolic actions of the organism, at any age and in any pathological process of deterioration or aging.
Recommended for puppies, healthy adults or dogs with liver or kidney insufficiencies.
A brief history of antioxidants
DECREASE OF THE SARCOPENIA, OSTEOPENIA AND DNA DAMAGE DUE TO OXIDATIVE STRESS IN DOGS, THROUGH THE ADMINISTRATION OF A FOOD SUPPLEMENT BASED ON RESVERATROL*.
The supplementation with Resveratrol and -Tocopherol could reduce the risk of sarcopenia in dogs by counteracting the oxidative stress
Sauzul Pharma LLC in partnership with Microsules Argentina Laboratory
Microsules Laboratory is a pharmaceutical Argentine company which has had presence for over 45 years producing an extensive selection of high quality medicines.
In a remarkably competitive market, our company of Argentine capitals has maintained a privileged position due to the constant updating of their equipment and the expertise of their professionals. Over time, this has led to sustained expansion and continuously enhanced product offering.
Nowadays, we develop three lines of products which are commercialized through their own sales force:
• Special treatments line (HIV - Oncology - Oncohematology)
• Pharma line (ambulatory medicines of high medical prescription)
• OTC line
Our model pharmaceutical plant is located in Garin, Buenos Aires Province. There is a warehouse, both primary and secondary conditioning areas, a quality control and assurance sector including all the necessary equipment, a dining room for employees and administration offices. Likewise, in December 2018 we opened a full new 2.000 square meters facility for the production of injectable and lyophilized oncological medicines.
Our company is positioned among the leading laboratory companies in the generic market. Today we commercialize more than 13.000.000 annual unities across the country with prompt potential expansion according to the markets needs.
There are currently more than 180 members of staff, this has been a growing number year after year and provides an outstanding service according to international standards.
All throughout these 45 years of experience it has been our strong conviction that proficiency led by constant upgrading is the best way to progress and upfront future challenges.